Effect of IL-12 Predose on Chronic IL-12–Induced Changes
| Parameter . | Vehicle × 5 . | IL-12 × 5 . | IL-12 (−14) + Vehicle × 5 . | IL-12 (−14) + IL-12 × 5 . |
|---|---|---|---|---|
| Serum TNF (U/mL) | 10.5 ± 6.9 | 26 ± 2.1* | 12.4 ± 4.3 | 32.8 ± 2.8* |
| Spleen TNF (U/g) | 15 ± 6.5 | 31.5 ± 12* | 14 ± 3.8 | 36.8 ± 10.6* |
| Serum sTNFR-P75 (ng/mL) | 20.6 ± 2 | 54.8 ± 3.4† | 23.2 ± 7.1 | 57.3 ± 3.5† |
| Serum IL-4 (pg/mL) | <5 | <5 | <5 | <5 |
| Serum IL-6 (U/mL) | <50 | <50 | <50 | <50 |
| Serum IL-10 (pg/mL) | <7.5 | <7.5 | <7.5 | <7.5 |
| Serum IFN-γ (pg/mL) | <1 | 367 ± 62.5† | <1 | 126 ± 37† |
| Spleen IFN-γ (pg/g) | <1 | 248 ± 36† | <1 | 29.6 ± 8† |
| Serum CS (ng/mL) | 42.1 ± 10 | 135.4 ± 19† | 51.2 ± 16 | 126 ± 18† |
| Glycemia (mg/100 mL) | 169 ± 2.9 | 138.7 ± 3.8* | 166 ± 4.2 | 154.2 ± 3.8 |
| Parameter . | Vehicle × 5 . | IL-12 × 5 . | IL-12 (−14) + Vehicle × 5 . | IL-12 (−14) + IL-12 × 5 . |
|---|---|---|---|---|
| Serum TNF (U/mL) | 10.5 ± 6.9 | 26 ± 2.1* | 12.4 ± 4.3 | 32.8 ± 2.8* |
| Spleen TNF (U/g) | 15 ± 6.5 | 31.5 ± 12* | 14 ± 3.8 | 36.8 ± 10.6* |
| Serum sTNFR-P75 (ng/mL) | 20.6 ± 2 | 54.8 ± 3.4† | 23.2 ± 7.1 | 57.3 ± 3.5† |
| Serum IL-4 (pg/mL) | <5 | <5 | <5 | <5 |
| Serum IL-6 (U/mL) | <50 | <50 | <50 | <50 |
| Serum IL-10 (pg/mL) | <7.5 | <7.5 | <7.5 | <7.5 |
| Serum IFN-γ (pg/mL) | <1 | 367 ± 62.5† | <1 | 126 ± 37† |
| Spleen IFN-γ (pg/g) | <1 | 248 ± 36† | <1 | 29.6 ± 8† |
| Serum CS (ng/mL) | 42.1 ± 10 | 135.4 ± 19† | 51.2 ± 16 | 126 ± 18† |
| Glycemia (mg/100 mL) | 169 ± 2.9 | 138.7 ± 3.8* | 166 ± 4.2 | 154.2 ± 3.8 |
Murine rIL-12, 400 ng/mouse, IP, was administered daily for 5 days, with or without an IL-12 predose (200 ng/mouse on day −14). Measurements were made 2 hours after the last dose. Data are means ± SD of five mice per group. The sensitivity of the TNF assay was 7.5 U/mL.
P < .05, † P < .01 v vehicle by Tukey's test.